ADT in prostate cancer treatment in 2022 – the choice or necessity? Review article
Article Sidebar
Published:
Sep 2, 2022
Keywords:
prostate cancer, androgen deprivation, novel hormonotherapy
Main Article Content
Abstract
The incidence of prostate cancer (PCa) is increasing. The treatment is local (surgery, radiotherapy) and/or systemic (hormonal therapy, chemotherapy). Androgen deprivation plays the key role in PCa therapy. Different drug combinations showed survival benefit for PCa patients. The paper addresses new treatment options at different stages of the disease.
Article Details
How to Cite
Drobniak , A., & Malik , L. (2022). ADT in prostate cancer treatment in 2022 – the choice or necessity?. Medycyna Faktow (J EBM), 15(3(56), 297-300. https://doi.org/10.24292/01.MF.0322.4
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Schulman CC , Irani J, Morote J. Deprivation therapy in prostate cancer: a European Expert Panel Review. Eur Urol Suppl. 2010; 9: 675-91.
2. Sternberg CN, Baskin-Bey ES, Watson M et al. Treatment patterns and characteristics of European patients with castration-resistant prostate cancer. BMC Urol. 2013; 13: 58.
3. Merseburger AS, Hammerer P, Rozet F et al. Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy? World J Urol. 2015; 33(8): 1079-85.
4. NCCN Guidelines. Prostate Cancer (access: 16.08.2022).
5. ESMO. CLINICAL PRACTICE GUIDELINES – PROSTATE CANCER (access: 16.08.2022).
6. Oefelein MG, Feng A, Scolieri MJ et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000; 56(6): 1021-4.
7. James ND, Sydes MR, Clarke NW et al. STAMPEDE Investigators Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016; 387(10024): 1163-77.
8. Fizazi K, Foulon S, Carles J et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022; 399(10336): 1695-707.
9. Overall Survival Results of PEACE-1 a Phase 3 Trial in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC) – Karim Fizazi, UroToday Home, ESMO 2021.
10. Attard G, Murphy L, Clarke NW et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 2022; 399(10323): 447-60.
11. Cattrini C Caffo O, De Giorgi U et al. Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review Cancers 2022; 14(7): 1792.
12. De Galiza Barbosa F, Queiroz MA, Nunes RF et al. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging. 2020; 20: 23.
2. Sternberg CN, Baskin-Bey ES, Watson M et al. Treatment patterns and characteristics of European patients with castration-resistant prostate cancer. BMC Urol. 2013; 13: 58.
3. Merseburger AS, Hammerer P, Rozet F et al. Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy? World J Urol. 2015; 33(8): 1079-85.
4. NCCN Guidelines. Prostate Cancer (access: 16.08.2022).
5. ESMO. CLINICAL PRACTICE GUIDELINES – PROSTATE CANCER (access: 16.08.2022).
6. Oefelein MG, Feng A, Scolieri MJ et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000; 56(6): 1021-4.
7. James ND, Sydes MR, Clarke NW et al. STAMPEDE Investigators Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016; 387(10024): 1163-77.
8. Fizazi K, Foulon S, Carles J et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022; 399(10336): 1695-707.
9. Overall Survival Results of PEACE-1 a Phase 3 Trial in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC) – Karim Fizazi, UroToday Home, ESMO 2021.
10. Attard G, Murphy L, Clarke NW et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 2022; 399(10323): 447-60.
11. Cattrini C Caffo O, De Giorgi U et al. Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review Cancers 2022; 14(7): 1792.
12. De Galiza Barbosa F, Queiroz MA, Nunes RF et al. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging. 2020; 20: 23.